Want to see JP:4883 full AI Analyst Report?
4883 Stock Chart & Stats
¥56.00
-¥3.00(-2.91%)
At close: 4:00 PM EST
¥56.00
-¥3.00(-2.91%)
Day’s Range― - ―
52-Week Range¥29.00 - ¥92.00
Previous CloseN/A
Volume5.80M
Average Volume (3M)620.72K
Market Cap
¥3.83B
Enterprise Value¥369.62
Total Cash (Recent Filing)¥3.02B
Total Debt (Recent Filing)¥270.00M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-24.03
Shares Outstanding106,464,096
10 Day Avg. Volume567,300
30 Day Avg. Volume620,716
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Bulls Say, Bears Say
Bulls Say
Proprietary Epigenetic PlatformA proprietary gene-regulation platform gives Modalis a defined technological foundation for developing multiple therapeutic candidates. If the approach translates into viable medicines, it could support platform monetization, partnering opportunities, and repeated pipeline creation beyond a single asset.
High-Unmet-Need FocusTargeting diseases with high unmet medical needs can support meaningful clinical and commercial opportunity if efficacy is demonstrated. Such programs may also be strategically attractive to development partners seeking differentiated treatments where existing options are inadequate or limited.
Debt-Free Balance SheetThe absence of reported debt reduces interest and refinancing burdens and gives the company a less leveraged financial structure. This provides some flexibility as management funds research and development, although it does not eliminate the need for external capital.
Bears Say
No Recent Revenue And Persistent LossesZero recent revenue and recurring billion-yen losses show that the company has not yet established a commercial earnings base. Until a candidate or platform generates meaningful income, operating performance will remain dependent on successful development and future financing.
Persistent And Worsening Cash BurnSustained negative operating and free cash flow means research activity is consuming cash rather than funding itself. Worsening burn increases dependence on external capital and could constrain development priorities if financing conditions or investor support become less favorable.
Shrinking Equity BaseMaterial equity erosion reflects the cumulative impact of repeated losses and reduces the financial cushion available to support long-duration biotechnology development. Continued losses could further weaken financial flexibility and increase reliance on additional capital raising.
Modalis Therapeutics Corporation News
4883 FAQ
What was Modalis Therapeutics Corporation’s price range in the past 12 months?
Modalis Therapeutics Corporation lowest stock price was ¥29.00 and its highest was ¥92.00 in the past 12 months.
What is Modalis Therapeutics Corporation’s market cap?
Modalis Therapeutics Corporation’s market cap is ¥3.83B.
When is Modalis Therapeutics Corporation’s upcoming earnings report date?
Modalis Therapeutics Corporation’s upcoming earnings report date is Nov 11, 2026 which is in 60 days.
How were Modalis Therapeutics Corporation’s earnings last quarter?
Modalis Therapeutics Corporation released its earnings results on Aug 10, 2026. The company reported -¥6.32 earnings per share for the quarter.
Is Modalis Therapeutics Corporation overvalued?
According to Wall Street analysts Modalis Therapeutics Corporation’s price is currently Overvalued.
Does Modalis Therapeutics Corporation pay dividends?
Modalis Therapeutics Corporation does not currently pay dividends.
What is Modalis Therapeutics Corporation’s EPS estimate?
Modalis Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modalis Therapeutics Corporation have?
Modalis Therapeutics Corporation has 106,464,096 shares outstanding.
What happened to Modalis Therapeutics Corporation’s price movement after its last earnings report?
Modalis Therapeutics Corporation reported an EPS of -¥6.32 in its last earnings report. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Modalis Therapeutics Corporation?
Currently, no hedge funds are holding shares in JP:4883
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Cyfuse Biomedical K.K.
―